NCT02542657View on ClinicalTrials.gov

Ixazomib with Pomalidomide, Clarithromycin and Dexamethasone in Treating Patients with Multiple Myeloma

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

October 31, 2015

Primary Completion Date

August 31, 2025

Study Completion Date

December 31, 2025

Conditions
Myeloma
Interventions
DRUG

Clarithromycin

Given PO

DRUG

Dexamethasone

Given PO

DRUG

Ixazomib Citrate

Given PO

DRUG

Pomalidomide

Given PO

Trial Locations (3)

92868

University of California Irvine, Orange

95817

University of California Davis Comprehensive Cancer Center, Sacramento

92093-0960

University of California San Diego, La Jolla

Sponsors

Collaborators (2)

Takeda
Celgene
All Listed Sponsors
collaborator

Takeda

INDUSTRY

collaborator

Celgene

INDUSTRY

lead

Joseph Tuscano

OTHER